Teresa Bitetti

New Capabilities

As of September 2026: Leading Mimrylo's commercial launch

Polycythemia vera has been treated with bloodletting for more than a century. On August 28, the FDA approved Mimrylo (rusfertide), the first drug mimicking hepcidin, the hormone that limits iron for red blood cell production.

Updated Sep 1